What is the efficacy of herbal medicine in the treatment of COVID-19 infection?

1. Coronavirus disease (COVID-19) Pandemic study. [Internet]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed April 1, 2020.Search in Google Scholar

2. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020;pii: dyaa033. DOI: 10.1093/ije/dyaa033. [Epub ahead of print]10.1093/ije/dyaa033Search in Google Scholar

3. Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect Dis. 2020;pii: S1473-3099(20)30129-8. DOI: 10.1016/S1473-3099(20)30129-8. [Epub ahead of print]10.1016/S1473-3099(20)30129-8Search in Google Scholar

4. Leung PC. The efficacy of Chinese medicine for SARS: a review of Chinese publications after the crisis. Am J Chin Med. 2007;35(4):575-81. DOI: 10.1142/S0192415X07005077.10.1142/S0192415X07005077Search in Google Scholar

5. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361(9374):2045-6. DOI: 10.1016/s0140-6736(03)13615-x.10.1016/S0140-6736(03)13615-XSearch in Google Scholar

6. Wu T, Yang X, Zeng X, Poole P. Traditional Chinese medicine in the treatment of acute respiratory tract infections. Respir Med. 2008;102(8):1093-8. DOI: 10.1016/j.rmed.2008.03.015.10.1016/j.rmed.2008.03.015713491918590956Search in Google Scholar

7. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670-95. DOI: 10.1016/j.bbagen.2013.02.008.10.1016/j.bbagen.2013.02.008367286223428572Search in Google Scholar

8. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARSCoV-2): A review and perspective. Int J Biol Sci. 2020;16(10):1708-17. DOI: 10.7150/ijbs.45538.10.7150/ijbs.45538709803632226288Search in Google Scholar

9. Luo W, Su X, Gong S, Qin Y, Liu W, Li J, et al. Anti-SARS coronavirus 3C-like protease effects of Rheum palmatum L. extracts. Bioscience Trends. 2009;3(4):124-6.Search in Google Scholar

10. Lau KM, Lee KM, Koon CM, Cheung CSF, Lau CP, Ho HM, et al. Immunomodulatory and anti-SARS activities of Houttuynia cordata. J Ethnopharmacol. 2008;118(1):79-85. DOI: 10.1016/j.jep.2008.03.018.10.1016/j.jep.2008.03.018712638318479853Search in Google Scholar

11. Gong SJ, Su XJ, Yu HP, Li J, Qin YJ, Xu Q, et al. A study on anti-SARS-CoV 3CL protein of flavonoids from litchi chinensis sonn core. Chinese Pharmacological Bulletin. 2008;24:699-700.Search in Google Scholar

12. Lin CW, Tsai FJ, Tsai CH, Lai CC, Wan L, Ho TY, et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005;68(1):36-42.10.1016/j.antiviral.2005.07.002711432116115693Search in Google Scholar

13. Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020;35(1):145-51. DOI: 10.1080/14756366.2019.1690480.10.1080/14756366.2019.1690480688243431724441Search in Google Scholar

14. Fung KP, Leung PC, Tsui KWS, Wan CCD, Wong KB, Waye MYM, et al. Immunomodulatory activities of the herbal formula Kwan Du Bu Fei Dang in healthy subjects: a randomised, double-blind, placebo-controlled study. Hong Kong Med J. 2011;17 Suppl 2:41-3.Search in Google Scholar

15. Yu MS, Lee J, Lee JM, Kim Y, Chin YW, Jee JG, et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg Med Chem Lett. 2012;22(12):4049-54. DOI: 10.1016/j.bmcl.2012.04.081.10.1016/j.bmcl.2012.04.081712743822578462Search in Google Scholar

16. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YS, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004;101(27):10012-7. DOI: 10.1073/pnas.0403596101.10.1073/pnas.040359610145415715226499Search in Google Scholar

17. Kuhn JH, Radoshitzky SR, Li W, Wong SK, Choe H, Farzan M. The SARS Coronavirus receptor ACE 2 A potential target for antiviral therapy. In: Holzenburg A, Bogner E, editors. New Concepts of Antiviral Therapy. Boston, MA: Springer US; 2006, p.397-418.10.1007/978-0-387-31047-3_15Search in Google Scholar

18. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562-9. DOI: 10.1038/s41564-020-0688-y.10.1038/s41564-020-0688-y709543032094589Search in Google Scholar

19. Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007;74(2):92-101. DOI: 10.1016/j.antiviral.2006.04.014.10.1016/j.antiviral.2006.04.014711433216730806Search in Google Scholar

20. Deng YF, Aluko RE, Jin Q, Zhang Y, Yuan LJ. Inhibitory activities of baicalin against renin and angiotensin-converting enzyme. Pharm Biol. 2012;50(4):401-6. DOI: 10.3109/13880209.2011.608076.10.3109/13880209.2011.60807622136493Search in Google Scholar

21. Takahashi S, Yoshiya T, Yoshizawa-Kumagaye K, Sugiyama T. Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean. Biomed Res. 2015;36(3):219-24. DOI: 10.2220/biomedres.36.219.10.2220/biomedres.36.21926106051Search in Google Scholar

22. Cheng PW, Ng LT, Chiang LC, Lin CC. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin Exp Pharmacol Physiol. 2006;33(7):612-6.10.1111/j.1440-1681.2006.04415.x716203116789928Search in Google Scholar

23. Chen CJ, Michaelis M, Hsu HK, Tsai CC, Yang KD, Wu YC, et al. Toona sinensis Roem tender leaf extract inhibits SARS coronavirus replication. J Ethnopharmacol. 2008;120(1):108-11.10.1016/j.jep.2008.07.048712724818762235Search in Google Scholar

24. Chan MC, Chan RW, Mok CK, Mak NK, Wong RN. Indirubin-3’-oxime as an antiviral and immunomodulatory agent in treatment of severe human influenza virus infection. Hong Kong Med J. 2018;24 Suppl 6(5):45-7.Search in Google Scholar

25. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69-71. DOI: 10.5582/bst.2020.01020.10.5582/bst.2020.0102031996494Search in Google Scholar

26. AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol. 2020;83:106455. Published online 2020 Apr 2. DOI: 10.1016/j.intimp.2020.106455.10.1016/j.intimp.2020.106455712819432272396Search in Google Scholar